Press Releases

RSS
  • Oct 6, 2015
    ENGLEWOOD, Colo., Oct. 6, 2015 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, today announced that it has acquired the rights to Primsol® (trimethoprim hydrochloride) oral solution from FSC Laboratories, Inc.  Primsol is the Company's second acquisition of a branded, revenue-generating p...
    Sep 28, 2015
    ENGLEWOOD, Colo., Sept. 28, 2015 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, today will host its inaugural quarterly conference call to review recent accomplishments and provide an overview of its business and growth strategy, as well as its financial results for the fiscal year ended Ju...
    Sep 21, 2015
    ENGLEWOOD, Colo., Sept. 21, 2015 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, announced today that the Company will host its inaugural quarterly conference call on Monday, September 28, 2015, at 4:30 p.m. ET.  The Company will review recent accomplishments and provide an overview of its...
    Sep 16, 2015
    ENGLEWOOD, Colo., Sept. 16, 2015 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, will present new data at the American Society for Reproductive Medicine's annual meeting. The data are from a study utilizing Aytu's MiOXSYS™ System to measure oxidative stress levels in semen, which is broad...
    Sep 9, 2015
    ENGLEWOOD, Colo., Sept. 9, 2015 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, announced today the appointment of Jonathan Heath McGrael as Vice President of Sales of Aytu Bioscience, effective September 16, 2015. Mr. McGrael has significant experience building healthcare sales organizatio...
    Sep 2, 2015
    ENGLEWOOD, Colo., Sept. 2, 2015 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, announced today that it has closed the final tranche of its planned private placement convertible note financing, raising a total of $5.175 million, which includes proceeds from two prior tranches totaling $3.175...
    Aug 13, 2015
    ENGLEWOOD, Colo., Aug. 13, 2015 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, announced today that its S-1 registration statement relating to the registration of 2,564,872 common shares owned by certain stockholders and issuable to certain warrant holders in Aytu's predecessor companies wa...
    Jul 7, 2015
    ENGLEWOOD, Colo., July 7, 2015 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, announced today that the company is now trading under the new symbol "AYTU," following its corporate name change, which became effective June 8, 2015. All stock trading, filings, and market related information wi...
    Jun 9, 2015
    ENGLEWOOD, Colo., June 9, 2015 /PRNewswire/ -- Aytu BioScience, Inc. (OTCMKTS: RSWN), a specialty healthcare company focused on developing treatments for urological and related conditions, today entered into an agreement with Jazz Pharmaceuticals (NASDAQ: JAZZ) to acquire Jazz Pharmaceuticals' rights to ProstaScint®, an imaging agent used to detect the extent and spread of prostate cancer that i...
    Jun 2, 2015
    ENGLEWOOD, Colo., June 2, 2015 /PRNewswire/ -- Rosewind Corporation (OTCQB: RSWN) announced that, after necessary state filings, the company will be known as Aytu BioScience, Inc., a specialty healthcare company focused on developing treatments for urological and related conditions.  The corporate name change was approved by shareholders at a special meeting of Rosewind Corp. shareholders held o...